BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 32265109)

  • 1. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
    J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
    Song P; Zhang J; Shang C; Zhang L
    Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
    Lee J; Choi Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Eur J Cancer; 2020 Jun; 132():150-158. PubMed ID: 32371248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
    Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
    Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.